Host |
Mouse |
Klon |
VFF-7 |
Format |
Purified |
Methode |
F, P, WB, FL |
Vorbehandlung |
Citrate |
Verdünnung |
1:200 (P) |
Isotyp |
Mouse IgG1 |
CD44v6
|
Zytomed Systems GmbH |
VFF-7 |
100 µg |
Purified |
RUO |
603-0983 |
-
|
Host |
Mouse |
Klon |
VFF-7 |
Format |
Purified |
Methode |
FL |
Isotyp |
Mouse IgG1 |
CD44v6 - FITC
|
Zytomed Systems GmbH |
VFF-7 |
100 Tests |
Purified |
RUO |
603-0985C |
-
|
Host |
Rat |
Klon |
YW62.3 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
Mouse spleen cells |
CD45 (LCA)
|
Zytomed Systems GmbH |
YW62.3 |
100 µg |
Purified |
RUO |
603-0993 |
-
|
Host |
Rabbit |
Klon |
ZR361 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
1 ml |
Concentrate |
CE/IVD |
Z2737RL |
-
|
Host |
Rabbit |
Klon |
ZR361 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
7 ml |
Concentrate |
CE/IVD |
Z2737RP |
-
|
Host |
Rabbit |
Klon |
ZR361 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
0.5 ml |
Concentrate |
CE/IVD |
Z2737RS |
-
|
Host |
Rabbit |
Klon |
ZR361 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasm |
CD45 (LCA)
|
Zeta Corporation |
ZR361 |
0.1 ml |
Concentrate |
CE/IVD |
Z2737RT |
-
|
Host |
Rabbit |
Klon |
ZR118 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
1 ml |
Concentrate |
CE/IVD |
Z2681RL |
-
|
Host |
Rabbit |
Klon |
ZR118 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
7 ml |
Concentrate |
CE/IVD |
Z2681RP |
-
|
Host |
Rabbit |
Klon |
ZR118 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
0.5 ml |
Concentrate |
CE/IVD |
Z2681RS |
-
|
Host |
Rabbit |
Klon |
ZR118 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human PTPRC protein |
Lokalisation |
Cell surface and cytoplasmic |
CD45RA
|
Zeta Corporation |
ZR118 |
0.1 ml |
Concentrate |
CE/IVD |
Z2681RT |
-
|
Host |
Mouse |
Klon |
2B11/PD7-26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
1.0 ml |
Concentrate |
CE/IVD |
Z2093ML |
-
|
Host |
Mouse |
Klon |
2B11/PD7-26 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
7 ml |
Ready-to-use |
CE/IVD |
Z2093MP |
-
|
Host |
Mouse |
Klon |
2B11/PD7-26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
0.5 ml |
Concentrate |
CE/IVD |
Z2093MS |
-
|
Host |
Mouse |
Klon |
2B11/PD7-26 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ + IgG1 /κ |
Verdünnung |
PD7/26/16: human peripheral blood lymphocytes maintained in T cell growth factor. 2B11: isolated neoplastic cells from T cell lymphoma |
Lokalisation |
Cell membrane |
CD45RB (LCA)
|
Zeta Corporation |
2B11/PD7-26 |
0.1 ml |
Concentrate |
CE/IVD |
Z2093MT |
-
|
Host |
Mouse |
Klon |
UCHL-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
1 ml |
Concentrate |
CE/IVD |
MOB043 |
-
|
Host |
Mouse |
Klon |
UCHL-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB043-01 |
-
|
Host |
Mouse |
Klon |
UCHL-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB043-05 |
-
|
Host |
Mouse |
Klon |
UCHL-1 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cell Membrane |
CD45RO
|
Diagnostic Biosystems |
UCHL-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM015 |
-
|
Host |
Mouse |
Klon |
UCHL1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Interleukin-2-dependent human T lymphocytes |
Lokalisation |
Cell membrane |
CD45RO
|
Zeta Corporation |
UCHL1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2036ML |
-
|
Host |
Mouse |
Klon |
UCHL1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Interleukin-2-dependent human T lymphocytes |
Lokalisation |
Cell membrane |
CD45RO
|
Zeta Corporation |
UCHL1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2036MP |
-
|
Host |
Mouse |
Klon |
UCHL1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Interleukin-2-dependent human T lymphocytes |
Lokalisation |
Cell membrane |
CD45RO
|
Zeta Corporation |
UCHL1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2036MS |
-
|
Host |
Mouse |
Klon |
UCHL1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil or lymph node. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
Interleukin-2-dependent human T lymphocytes |
Lokalisation |
Cell membrane |
CD45RO
|
Zeta Corporation |
UCHL1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2036MT |
-
|
Host |
Mouse |
Klon |
TS2/7 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
CD49a (Integrin alpha1)
|
Zytomed Systems GmbH |
TS2/7 |
200 µg |
Purified |
RUO |
603-1115 |
-
|
Host |
Rat |
Klon |
YTH34.5 |
Format |
Purified |
Methode |
F, P, FL |
Vorbehandlung |
optional: Trypsin or Pronase |
Positivkontrolle |
Tonsil |
Verdünnung |
1:20 (P) |
Isotyp |
Rat IgG2b |
CD52 (CAMPATH 1)
|
Zytomed Systems GmbH |
YTH34.5 |
20 µg (20 µl) |
Purified |
RUO |
603-2225 |
-
|
Host |
Rat |
Klon |
YTH34.5 |
Format |
Purified |
Methode |
F, P, FL, EL, IP, WB |
Vorbehandlung |
optional: Trypsin or Pronase |
Positivkontrolle |
Tonsil |
Verdünnung |
1:20 - 1:40 (P) |
Isotyp |
Rat IgG2b |
CD52 (CAMPATH 1)
|
Zytomed Systems GmbH |
YTH34.5 |
0.2 mg (200 µl) |
Purified |
RUO |
603-2226 |
-
|
Host |
Mouse |
Klon |
15.2 |
Format |
Purified |
Methode |
F, P, IP, FL |
Positivkontrolle |
Human Tonsil |
Verdünnung |
1:50 -1:100 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human monocytes |
CD54 (I-CAM-1)
|
Zytomed Systems GmbH |
15.2 |
100 µg |
Purified |
RUO |
603-1211 |
-
|
Host |
Mouse |
Klon |
15.2 |
Format |
Purified |
Methode |
F, P, FL |
Positivkontrolle |
Human Tonsil |
Verdünnung |
1:50 -1:100 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human monocytes |
CD54 (I-CAM-1)
|
Zytomed Systems GmbH |
15.2 |
20 µg |
Purified |
RUO |
603-1212 |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Neuroblastom |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
1 ml |
Concentrate |
CE/IVD |
MOB261 |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Neuroblastom |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB261-01 |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Neuroblastom |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB261-05 |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Neuroblastom |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell Membrane |
CD56
|
Diagnostic Biosystems |
123C3.D5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM110 |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
1.0 ml |
Concentrate |
CE/IVD |
Z2038ML |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
7 ml |
Ready-to-use |
CE/IVD |
Z2038MP |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
0.5 ml |
Concentrate |
CE/IVD |
Z2038MS |
-
|
Host |
Mouse |
Klon |
123C3.D5 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Neuroblastoma, neuroendocrine carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Membrane preparation of a small cell lung carcinoma |
Lokalisation |
Cell membrane |
CD56
|
Zeta Corporation |
123C3.D5 |
0.1 ml |
Concentrate |
CE/IVD |
Z2038MT |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
1 ml |
Concentrate |
CE/IVD |
MOB163 |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB163-01 |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB163-05 |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgM |
Lokalisation |
Cell Membrane |
CD57
|
Diagnostic Biosystems |
NK-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM130 |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Human peripheral blood mononuclear cells |
Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
1ml |
Concentrate |
CE/IVD |
Z2111ML |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
- |
Isotyp |
IgM |
Verdünnung |
Human peripheral blood mononuclear cells |
Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2111MP |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Human peripheral blood mononuclear cells |
Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2111MS |
-
|
Host |
Mouse |
Klon |
NK-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lymph node or tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgM |
Verdünnung |
Human peripheral blood mononuclear cells |
Lokalisation |
Cell membrane |
CD57
|
Zeta Corporation |
NK-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2111MT |
-
|
Host |
Mouse |
Klon |
MEM-43 |
Format |
Purified |
Methode |
F, P, EL, WB, FL, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Isotyp |
Mouse IgG2a |
CD59
|
Zytomed Systems GmbH |
MEM-43 |
200 µg |
Purified |
RUO |
603-1254 |
-
|
Host |
Rat |
Klon |
YTH53.1 |
Format |
Purified |
Methode |
F, WB, FL |
Isotyp |
Rat IgG2b |
Verdünnung |
Human peripheral blood T cells |
CD59
|
Zytomed Systems GmbH |
YTH53.1 |
200 µg |
Purified |
RUO |
603-1259 |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
1 ml |
Concentrate |
CE/IVD |
MOB164 |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
0.1 ml |
Concentrate |
CE/IVD |
MOB164-01 |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
0.5 ml |
Concentrate |
CE/IVD |
MOB164-05 |
-
|
Host |
Mouse |
Klon |
Y2/51 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate or Fast Enzyme (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cell Membrane |
CD61
|
Diagnostic Biosystems |
Y2/51 |
6 ml |
Ready-to-use |
CE/IVD |
PDM064 |
-
|